A NEW ERA OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION IN CHOLANGIOCARCINOMA

被引：2
|
作者：
Lamarca, A. [1 ,2 ]
Moreno, V. [3 ]
Gambardella, V. [4 ,5 ]
Cervantes, A. [4 ,5 ]
机构：
[1] Fdn Jimenez Diaz Univ Hosp, Oncohealth Inst, Dept Med Oncol, Madrid, Spain
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England
[3] Fdn Jimenez Diaz Univ Hosp, Dept Med Oncol, START FJD Phase Unit 1, Madrid, Spain
[4] Univ Valencia, Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain
[5] Inst Salud Carlos III, CIBERONC, Madrid, Spain
来源：
ESMO OPEN | 2023年 / 8卷 / 06期
关键词：
METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; EFFICACY;
D O I：
10.1016/j.esmoop.2023.102032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Role of the fibroblast growth factor receptor axis in cholangiocarcinoma
    Ang, Celina
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (07) : 1116 - 1122
  • [2] Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened
    Rizvi, Sumera
    Gores, Gregory J.
    HEPATOLOGY, 2018, 68 (06) : 2428 - 2430
  • [3] Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
    Graham, Rondell P.
    Fritcher, Emily G. Barr
    Pestova, Ekaterina
    Schulz, John
    Sitailo, Leonid A.
    Vasmatzis, George
    Murphy, Stephen J.
    McWilliams, Robert R.
    Hart, Steven N.
    Halling, Kevin C.
    Roberts, Lewis R.
    Gores, Gregory J.
    Couch, Fergus J.
    Zhang, Lizhi
    Borad, Mitesh J.
    Kipp, Benjamin R.
    HUMAN PATHOLOGY, 2014, 45 (08) : 1630 - 1638
  • [4] A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma
    Ilyas, Sumera I.
    Yamada, Daisaku
    Hirsova, Petra
    Bronk, Steven F.
    Werneburg, Nathan W.
    Krishnan, Anuradha
    Salim, Warda
    Zhang, Liang
    Trushina, Eugenia
    Truty, Mark J.
    Gores, Gregory J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (15) : 8031 - 8047
  • [5] Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma
    Kassaye, Isabell
    Alyafaie, Adam
    Zhang, Karen
    Lifton, Jacob
    Gordan, John D.
    Kelley, Robin Kate
    Yung, Madeline
    JAMA OPHTHALMOLOGY, 2024, 142 (12) : 1109 - 1113
  • [6] Pemigatinib Fibroblast growth factor receptor inhibitor Treatment of cholangiocarcinoma
    Franco, B.
    Clarke, P.
    Carotenuto, P.
    DRUGS OF THE FUTURE, 2019, 44 (12) : 923 - 932
  • [7] Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma
    Kabashima, Ayano
    Hirsova, Petra
    Bronk, Steven F.
    Hernandez, Matthew C.
    Truty, Mark J.
    Ilyas, Sumera I.
    Kaufmann, Scott H.
    Gores, Gregory J.
    JOURNAL OF HEPATOLOGY, 2018, 68 (06) : 1228 - 1238
  • [8] The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma
    Ruff, Samantha M.
    Roychowdhury, Sameek
    Pawlik, Timothy M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 779 - 788
  • [9] Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
    Borad, Mitesh J.
    Gores, Gregory J.
    Roberts, Lewis R.
    CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (03) : 264 - 268
  • [10] Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
    Lamarca, Angela
    Ostios, Lorena
    Mcnamara, Mairead G.
    Garzon, Carlos
    Gleeson, Jack P.
    Edeline, Julien
    Herrero, Ana
    Hubner, Richard A.
    Moreno, Victor
    Valle, Juan W.
    CANCER TREATMENT REVIEWS, 2023, 121
12345